How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

NIS2 puts identity and access controls under the spotlight, with weak passwords and poor authentication now a compliance risk ...

Nutanix, a leader in hybrid multi-cloud computing, is introducing new capabilities to its Nutanix Cloud Platform (NCP) solution—designed to give enterprises greater flexibility to deploy and govern ...

Mitchell Grant is a self-taught investor with over 5 years of experience as a financial trader. He is a financial content strategist and creative content editor. Mandatory binding arbitration requires ...

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Eric's career includes extensive work in both public and corporate accounting with ...